JP7738377B2 - 神経炎症の調節 - Google Patents

神経炎症の調節

Info

Publication number
JP7738377B2
JP7738377B2 JP2021552522A JP2021552522A JP7738377B2 JP 7738377 B2 JP7738377 B2 JP 7738377B2 JP 2021552522 A JP2021552522 A JP 2021552522A JP 2021552522 A JP2021552522 A JP 2021552522A JP 7738377 B2 JP7738377 B2 JP 7738377B2
Authority
JP
Japan
Prior art keywords
igfbpl1
hsp60
administration
mice
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2021552522A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022524325A5 (https=
JP2022524325A (ja
JPWO2020180865A5 (https=
Inventor
フェン チェン，ドン
チョ，キン－サン
ジ，ミン
Original Assignee
マサチューセッツ アイ アンド イヤー インファーマリー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by マサチューセッツ アイ アンド イヤー インファーマリー filed Critical マサチューセッツ アイ アンド イヤー インファーマリー
Publication of JP2022524325A publication Critical patent/JP2022524325A/ja
Publication of JP2022524325A5 publication Critical patent/JP2022524325A5/ja
Publication of JPWO2020180865A5 publication Critical patent/JPWO2020180865A5/ja
Priority to JP2025017178A priority Critical patent/JP2025087689A/ja
Application granted granted Critical
Publication of JP7738377B2 publication Critical patent/JP7738377B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A61K38/1754—Insulin-like growth factor binding proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/30—Insulin-like growth factors, i.e. somatomedins, e.g. IGF-1, IGF-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A61K9/0051—Ocular inserts or implants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Toxicology (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
JP2021552522A 2019-03-04 2020-03-03 神経炎症の調節 Active JP7738377B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2025017178A JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962813556P 2019-03-04 2019-03-04
US62/813,556 2019-03-04
PCT/US2020/020794 WO2020180865A1 (en) 2019-03-04 2020-03-03 Modulating neuroinflammation

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2025017178A Division JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Publications (4)

Publication Number Publication Date
JP2022524325A JP2022524325A (ja) 2022-05-02
JP2022524325A5 JP2022524325A5 (https=) 2023-03-10
JPWO2020180865A5 JPWO2020180865A5 (https=) 2023-03-10
JP7738377B2 true JP7738377B2 (ja) 2025-09-12

Family

ID=72337602

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021552522A Active JP7738377B2 (ja) 2019-03-04 2020-03-03 神経炎症の調節
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2025017178A Pending JP2025087689A (ja) 2019-03-04 2025-02-04 神経炎症の調節

Country Status (7)

Country Link
US (1) US20220143139A1 (https=)
EP (1) EP3934674A4 (https=)
JP (2) JP7738377B2 (https=)
KR (1) KR20210148163A (https=)
CN (1) CN113795266A (https=)
CA (1) CA3132333A1 (https=)
WO (1) WO2020180865A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10842849B2 (en) 2011-02-28 2020-11-24 The Schepens Eye Research Institute, Inc. Methods for promoting neuronal outgrowth by insulin-like growth factor binding protein-like 1 (IGFBPL-1) in glaucoma or leber's optic neuropathy
KR102829678B1 (ko) * 2021-12-13 2025-07-04 차의과학대학교 산학협력단 신경전구세포를 포함하는 시신경병증의 예방 또는 치료용 약학 조성물
WO2024220474A1 (en) * 2023-04-21 2024-10-24 The Schepens Eye Research Institute, Inc. Methods of treating age-related macular degeneration targeting igfbpl-1
AU2024308069A1 (en) * 2023-06-27 2026-02-05 Firecyte Therapeutics, Inc. Insulin-like growth factor binding protein like 1 (igfbpl1) compositions and methods of use thereof

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529292A (ja) 2010-04-13 2013-07-18 エム−ラブ・アクチェンゲゼルシャフト 緑内障の診断方法
US20140128322A1 (en) 2011-02-28 2014-05-08 Dong Feng Chen Compositions for Controlling Neuronal Outgrowth

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090202618A1 (en) * 2003-11-24 2009-08-13 Yeda Research & Development Co. Ltd Dna vaccines encoding hsp60 peptide fragments for treating autoimmune diseases
KR20080031474A (ko) * 2005-07-27 2008-04-08 유니버시티 오브 플로리다 리서치 파운데이션, 아이엔씨. 안구 질환의 치료를 위한 열충격의 사용

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2013529292A (ja) 2010-04-13 2013-07-18 エム−ラブ・アクチェンゲゼルシャフト 緑内障の診断方法
US20140128322A1 (en) 2011-02-28 2014-05-08 Dong Feng Chen Compositions for Controlling Neuronal Outgrowth

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Investigative Ophthalmology & Visual Science，2018年07月，Vol.59，6128
Investigative Ophthalmology & Visual Science，2018年07月，Vol.59，6142

Also Published As

Publication number Publication date
EP3934674A1 (en) 2022-01-12
KR20210148163A (ko) 2021-12-07
CA3132333A1 (en) 2020-09-10
US20220143139A1 (en) 2022-05-12
WO2020180865A1 (en) 2020-09-10
JP2025087689A (ja) 2025-06-10
CN113795266A (zh) 2021-12-14
JP2022524325A (ja) 2022-05-02
EP3934674A4 (en) 2022-11-16

Similar Documents

Publication Publication Date Title
JP7738377B2 (ja) 神経炎症の調節
US12295985B2 (en) Methods of reducing severity of glaucoma by intravitreal administration of insulin-like growth factor binding protein-like 1 (IGFBPL1)
He et al. Topical administration of a suppressor of cytokine signaling-1 (SOCS1) mimetic peptide inhibits ocular inflammation and mitigates ocular pathology during mouse uveitis
Vu et al. CD4+ T-cell responses mediate progressive neurodegeneration in experimental ischemic retinopathy
Dando et al. A case of mistaken identity: CD11c‐eYFP+ cells in the normal mouse brain parenchyma and neural retina display the phenotype of microglia, not dendritic cells
Liu et al. Overexpression of BMP4 protects retinal ganglion cells in a mouse model of experimental glaucoma
AU2007264682B2 (en) Method of treatment of age-related macular degeneration
Simon et al. A rat model for acute rise in intraocular pressure: immune modulation as a therapeutic strategy
Schwartz Harnessing the immune system for neuroprotection: therapeutic vaccines for acute and chronic neurodegenerative disorders
EP3675889A2 (en) Angio-3 for treatment of retinal angiogenic diseases
CN115227824A (zh) 免疫检查点的抑制剂在制备治疗青光眼和其他眼部免疫损伤机制相关疾病药物中的应用
US10188679B2 (en) Human monocyte sub-population for treatment of eye diseases and disorders
JP2023521155A (ja) 網膜神経障害を予防及び治療するための方法及び組成物
US20210046002A1 (en) Amelioration of autoimmune uveitis through blockade of csf1r
Nussenblatt Vogt–Koyanagi–Harada syndrome
Yao et al. Clinical characteristics of acyclovir-resistant herpetic keratitis and experimental studies of isolates
US20250281529A1 (en) Treatment of diseases and conditions of the eye
US20250381195A1 (en) Methods of Treating Diabetic Macular Edema
RU2788097C2 (ru) Терапевтические и нейропротекторные пептиды
Cheng et al. Rag1−/− mice with T and B lymphocyte deficiency exhibit milder retinal inflammatory response and retinal ganglion cell injury after optic nerve crush
WO2025173411A1 (ja) 網膜神経節細胞分化誘導用キット、医薬組成物及び緑内障モデル
CN113194964A (zh) 神经保护性组合物及其用途

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230302

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20230302

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240220

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240520

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240722

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20241008

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250204

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20250708

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20250804

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250806

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20250804

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20250829

R150 Certificate of patent or registration of utility model

Ref document number: 7738377

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150